Chemours Q2 Loss Narrows, but Negative Equity and Surging Legal/Environmental Reserves Signal Deepening Distress
CC sits 43% above its 52-week low of $10.44.
Summary
Chemours' Q2 2026 10-Q reveals a $274M net loss, negative stockholders' equity of $48M, and a sharp increase in environmental and litigation reserves to $1.45 billion combined, underscoring the escalating financial toll of its PFAS liabilities.
Key Events · Earnings and Guidance · CC
-
Q2 Net Loss of $274M
Net loss attributable to Chemours was $274M ($1.81/share) vs. a $380M loss in Q2 2025. Revenue was flat at $1.59B, but SG&A surged to $469M from $424M due to higher environmental and litigation costs.
-
Negative Stockholders' Equity
Total equity fell to negative $48M at June 30, 2026, from positive $251M at year-end 2025, driven by a $208M deferred tax valuation allowance and the net loss.
-
Environmental Reserves Surge to $795M
Environmental remediation liabilities increased $177M to $795M, including $141M for expanded off-site drinking water programs at Washington Works and Chambers Works under the 2026 Consent Decree.
-
Litigation Accruals Jump to $658M
Accrued litigation rose $174M to $658M, with $269M for the New Jersey PFAS settlement and $203M for North Carolina matters, reflecting new probable loss estimates.
Analysis · CC · Industrial Applications And Services
Chemours posted a $274M net loss for Q2 2026, an improvement from the $380M loss a year ago, but the balance sheet tells a darker story. Stockholders' equity flipped to negative $48M, driven by a $208M deferred tax valuation allowance and a $141M increase in environmental remediation reserves tied to the 2026 Consent Decree. Accrued litigation jumped $174M to $658M, reflecting new reserves for the New Jersey PFAS settlement and North Carolina claims. While a $266M land sale gain provided a one-time boost, the company's ability to absorb future PFAS and environmental liabilities is increasingly strained. The 10-Q confirms the company has sufficient liquidity through August 2027, but the mounting reserves and negative equity raise serious questions about long-term solvency if litigation outcomes worsen.
How filings like this one have moved
In the 30 days to Sep 20, 2026, 39.1% of the 338 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.42%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CC was trading at $14.94 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $10.44 to $28.67. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.